ERICD and urinary bladder cancer: A CRISPR-dCas9-VPR targeting ERIC plasmid was constructed and transfected into bladder cancer cell lines T24 and 5,637 to detect the effect on proliferation, invasion, apoptosis and other aspects of bladder cancer cell lines and reveal its function.